Research material and lot documents.
BPC-157 is a peptide of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The records also call it Bepecin and PL-14736. Curo's recovery and regenerative research catalog lists a BPC-157 5mg vial.
BPC stands for Body Protection Compound. A 1993 overview described a gastric juice peptide named BPC and a 15 amino acid fragment of it, BPC 157, that the authors thought was essential for its activity. A 2011 study of rat tendon cells describes BPC-157 as a partial sequence of a compound "discovered in and isolated from human gastric juice". Sources: 1993 overview of BPC and BPC 157, PMID 8298609 and 2011 rat tendon-cell study, PMID 21030672.
FDA's briefing document for its July 2026 advisory committee, dated May 11, 2026, says: "BPC-157 is also known as Bepecin or PL-14736, which is a peptide that is reported to be comprised of 15 amino acids." Source: FDA briefing document, BPC-157-related bulk drug substances.
PubChem compound identifier (CID) 9941957.
Molecular formula C62H98N16O22 and molecular weight 1419.5 g/mol.
CAS number 137525-51-0 for the free base.
FDA unique ingredient identifier (UNII) 8ED8NXK95P for the free base and PAR2FC72XP for the acetate salt.
Other names in the records: PL-10, PLD-116 and PL-14736.
Sources: PubChem BPC-157 record, CID 9941957, FDA UNII record 8ED8NXK95P and the identifier table in the FDA briefing document.
These identifiers describe the reference compound. They do not describe what is in a particular vial. The FDA UNII page states: "UNII availability does not imply any regulatory review or approval."
The name BPC-157 covers more than one form. FDA's briefing document says BPC-157 "is a common name and not a United States Adopted Name (USAN)" and that "FDA has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name." The document lists BPC-157 (free base) and BPC-157 acetate with different UNII and CAS numbers and calls them different bulk drug substances. Source: FDA briefing document, section II.A.
The primary-source ledger for this site is a Google Doc: Open the BPC-157 source ledger.
Most published work uses rats, other animals or cultured cells. A 2025 systematic review searched the literature through June 3, 2024 and included 36 studies, 35 of them preclinical and one clinical. Source: 2025 systematic review in the HSS Journal, PMID 40756949. The BPC-157 research page lists the studies by model, the small human reports and the registry records.
FDA's briefing document dated May 11, 2026 states that there is "no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for BPC-157 (free base) or its acetate form, and neither is a component of an FDA-approved drug." The BPC-157 FDA status page gives that record with the other FDA dates and the WADA listing.
No. BPC-157 is one peptide. TB-500 is a different substance, and FDA's meeting page lists the two as separate entries. The combination has its own research record, which the Wolverine peptide site covers.
Lot reports are grouped by lot number in Curo's lot certificate library. The BPC-157 for sale page explains how to read a listing against the identifiers above.
BPC stands for Body Protection Compound, and BPC 157 is the name the 1993 authors gave to the 15 amino acid fragment. Source: 1993 overview, PMID 8298609.
The records use both names for one peptide. FDA's briefing document says BPC-157 "is also known as Bepecin or PL-14736", and PubChem lists PL-14736 as a synonym of CID 9941957. Sources: FDA briefing document and PubChem BPC-157 record, CID 9941957.
A 2025 narrative review states that "human data are extremely limited." The BPC-157 research page lists the three small human reports and the registry records. Source: 2025 narrative review, PMID 40789979.